AU2006267090B2 - Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity - Google Patents

Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity Download PDF

Info

Publication number
AU2006267090B2
AU2006267090B2 AU2006267090A AU2006267090A AU2006267090B2 AU 2006267090 B2 AU2006267090 B2 AU 2006267090B2 AU 2006267090 A AU2006267090 A AU 2006267090A AU 2006267090 A AU2006267090 A AU 2006267090A AU 2006267090 B2 AU2006267090 B2 AU 2006267090B2
Authority
AU
Australia
Prior art keywords
less
antibody
antibodies
months
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006267090A
Other languages
English (en)
Other versions
AU2006267090A1 (en
Inventor
Ezio Bonvini
Leslie S. Johnson
Scott Koenig
Ronald Wilder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provention Bio Inc
Original Assignee
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc filed Critical Provention Bio Inc
Publication of AU2006267090A1 publication Critical patent/AU2006267090A1/en
Priority to AU2013200924A priority Critical patent/AU2013200924A1/en
Application granted granted Critical
Publication of AU2006267090B2 publication Critical patent/AU2006267090B2/en
Assigned to PROVENTION BIO, INC. reassignment PROVENTION BIO, INC. Request for Assignment Assignors: MACROGENICS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
AU2006267090A 2005-07-11 2006-07-11 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity Active AU2006267090B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013200924A AU2013200924A1 (en) 2005-07-11 2013-02-15 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69851705P 2005-07-11 2005-07-11
US60/698,517 2005-07-11
PCT/US2006/027386 WO2007009064A2 (en) 2005-07-11 2006-07-11 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013200924A Division AU2013200924A1 (en) 2005-07-11 2013-02-15 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

Publications (2)

Publication Number Publication Date
AU2006267090A1 AU2006267090A1 (en) 2007-01-18
AU2006267090B2 true AU2006267090B2 (en) 2013-03-07

Family

ID=37637980

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006267090A Active AU2006267090B2 (en) 2005-07-11 2006-07-11 Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

Country Status (8)

Country Link
US (1) US8663634B2 (enExample)
EP (2) EP1904105A4 (enExample)
JP (2) JP2009500457A (enExample)
AU (1) AU2006267090B2 (enExample)
CA (1) CA2614640A1 (enExample)
IL (1) IL188592A (enExample)
SG (3) SG177944A1 (enExample)
WO (1) WO2007009064A2 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
EP1753783B1 (en) 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
SG177944A1 (en) 2005-07-11 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
BRPI0615745A2 (pt) * 2005-09-12 2011-05-24 Novimmune Sa formulação de anticorpo anti-cd3
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
AU2007260687B2 (en) 2006-06-14 2013-12-12 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
EP2094302A4 (en) * 2006-12-21 2010-12-08 Macrogenics Inc METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY
CN103694350B (zh) * 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
CN102027017A (zh) * 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
JP5604311B2 (ja) * 2008-03-13 2014-10-08 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
RU2540013C2 (ru) * 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
BRPI0906309A2 (pt) 2008-04-02 2020-05-26 Macrogenics, Inc Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
CA2726845C (en) 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
CA2738598C (en) * 2008-09-29 2017-11-21 Biotest Ag Composition for treating disease
WO2011047172A1 (en) * 2009-10-14 2011-04-21 Celtaxsys, Inc. Method of treating inflammation
US20120269826A1 (en) * 2009-10-20 2012-10-25 Mckee Charlotte Anti-cd3 antibody dosing in autoimmune disease
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2525813B1 (en) 2010-01-20 2017-01-04 Merck Sharp & Dohme Corp. Anti-ilt5 antibodies and ilt5-binding antibody fragments
EP2525822B1 (en) 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US20130115207A1 (en) * 2010-04-09 2013-05-09 The General Hospital Corporation Methods for the treatment of autoimmune diseases
US20130095121A1 (en) * 2010-06-25 2013-04-18 Aoife Brennan Methods of treating patients with immune-related diseases
WO2012098238A1 (en) * 2011-01-21 2012-07-26 Novimmune S.A. Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EA033677B1 (ru) 2011-05-21 2019-11-15 Macrogenics Inc Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
ES2924722T3 (es) 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
CA2915412A1 (en) * 2012-06-14 2013-12-19 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
EP2895203A4 (en) * 2012-06-15 2016-09-28 Imaginab Inc ANTIGENBINDING CONSTRUCTS FOR CD3
US9511110B2 (en) * 2012-09-27 2016-12-06 Perle Bioscience, Inc. Generation of new pancreatic beta cells
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
PL3129483T3 (pl) * 2014-04-08 2019-05-31 Fraunhofer Ges Forschung Terapia skojarzona do leczenia chorób autoimmunologicznych
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
CN115960230A (zh) 2015-08-07 2023-04-14 伊麦吉纳博公司 靶向分子的抗原结合构建体
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
IL265484B1 (en) 2016-09-21 2025-09-01 Aptevo Res & Development Llc Cd123 binding proteins and related compositions and methods
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR102592176B1 (ko) 2018-01-05 2023-10-20 플레이틀렛 바이오제네시스, 인크. 거핵구 생성을 위한 조성물 및 방법
WO2020006539A1 (en) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
WO2020250940A1 (ja) * 2019-06-11 2020-12-17 小野薬品工業株式会社 免疫抑制剤
WO2021195544A1 (en) * 2020-03-27 2021-09-30 Platelet Biogenesis, Inc. Novel anucleated cells for the treatment of diseases
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
IL302816A (en) * 2020-11-09 2023-07-01 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
TW202448505A (zh) 2023-03-01 2024-12-16 美商普泛森生技公司 用於治療第1型糖尿病的方法及組成物
TW202506177A (zh) 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法
TW202521153A (zh) 2023-07-27 2025-06-01 美商普泛森生技公司 治療第1型糖尿病之方法
EP4574174A1 (en) * 2023-12-19 2025-06-25 Jack Elands Novel antibody-drug conjugates comprising an anti-(tcr)-cd3-complex binding antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047531A2 (en) * 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51133489A (en) 1975-05-14 1976-11-19 Tokyo Daigaku Process for producing microbial components of pseudomonas aeruginosa h aving antimicrobial and antitumor activities
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4658019A (en) 1979-04-26 1987-04-14 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4221794A (en) 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US5078998A (en) 1985-08-02 1992-01-07 Bevan Michael J Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4882424A (en) 1987-05-11 1989-11-21 Dana-Farber Cancer Institute, Inc. Activation antigen
IL92382A (en) 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991001143A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Stable vaccine compositions containing interleukins
SE8903100D0 (sv) 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
EP0497883B1 (en) 1989-10-27 1998-07-15 Arch Development Corporation Compositions and their use for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ZA91463B (en) 1990-01-25 1992-09-30 Bristol Myers Squibb Co Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
JPH06508501A (ja) 1990-07-02 1994-09-29 ブリストル―マイアーズ　スクイブ　カンパニー Ｂ細胞上のｃｄ２８レセプターに対するリガンドおよび該リガンドを用いた細胞間相互作用の調節方法
JPH06505396A (ja) 1991-03-08 1994-06-23 サイトメッド，インコーポレイテッド 可溶性ｃｄ２８タンパク質およびそれを用いる治療方法
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
EP0637963B1 (en) 1992-04-07 2004-08-04 The Regents of the University of Michigan Cd28 pathway immunoregulation
AU4535893A (en) 1992-06-15 1994-01-04 Regents Of The University Of California, The Screening assay for the identification of immunosuppressive drugs
AU6586494A (en) 1993-04-14 1994-11-08 United States Of America As Represented By The Secretary Of The Navy, The Transgenic animal model for autoimmune diseases
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU7107794A (en) 1993-06-10 1995-01-03 Regents Of The University Of Michigan, The Cd28 pathway immunosuppression
WO1995003408A1 (en) 1993-07-26 1995-02-02 Dana-Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor
US7041289B1 (en) 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
JP2003531816A (ja) 1999-10-01 2003-10-28 バイオトランスプラント，インコーポレイテッド 遺伝子導入産物に機能的寛容を誘導する方法
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US20030216551A1 (en) 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
WO2003105896A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a beta cell resting compound
WO2003105897A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2005048935A2 (en) 2003-11-14 2005-06-02 Brigham And Women's Hospital, Inc. Methods of modulating immunity
AU2005213449A1 (en) * 2004-02-04 2005-08-25 The La Jolla Institute For Allergy And Immunology Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
EP1753783B1 (en) 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
SG177944A1 (en) * 2005-07-11 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
JP2009539841A (ja) 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
EP2094302A4 (en) 2006-12-21 2010-12-08 Macrogenics Inc METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047531A2 (en) * 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Friend, P.J. et al. 1999 Transplant. vol. 68, pp.1632-1637 *
Hering, B.J. et al. 2004 Ameri. J. Transplant. vol. 4, pp. 390-401 *
Herold, K.C. et al. 2002 N. Eng. J. Med. vol. 346, pp. 1692-1698 *
Herold, K.C. et al. 2003 J. Clin. Invest. vol. 111, pp. 409-418 *
Herold, K.C. et al. 2005 Diabetes vol. 54, pp. 1763-1769 *
Keymeulen, B. et al. 2005 N. Engl. J. Med. vol. 352, pp. 2598-2608 *
Utset, T.O. et al. 2002 J. Rheumatol. 2002 vol. 29, pp. 1907-1913 *
von Herrath, M.G. et al. 2002 J. Immunol. vol. 168, pp. 933-941 *

Also Published As

Publication number Publication date
AU2006267090A1 (en) 2007-01-18
CA2614640A1 (en) 2007-01-18
EP2497496A3 (en) 2013-02-20
IL188592A (en) 2013-08-29
IL188592A0 (en) 2008-04-13
JP2009500457A (ja) 2009-01-08
JP2013005798A (ja) 2013-01-10
SG177944A1 (en) 2012-02-28
SG163615A1 (en) 2010-08-30
US20070077246A1 (en) 2007-04-05
SG10201504917PA (en) 2015-07-30
WO2007009064A3 (en) 2009-04-23
EP2497496A2 (en) 2012-09-12
EP1904105A2 (en) 2008-04-02
US8663634B2 (en) 2014-03-04
EP1904105A4 (en) 2010-02-17
WO2007009064A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
AU2006267090B2 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AU2007260687B2 (en) Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
US20100015142A1 (en) Methods for the treatment of lada and other adult- onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity
US20120034221A1 (en) T-Cell Receptor Antibodies And Methods of Use Thereof
US10301390B2 (en) Anti-IFNAR1 antibodies with reduced Fc ligand affinity
CA2662340C (en) Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AU2018274215B2 (en) Antibody-cytokine engrafted proteins and methods of use for immune related disorders
AU2018344417A1 (en) CD3/CD33 bispecific binding molecules
US20240239912A1 (en) Targeted reduction of activated immune cells
AU2013200924A1 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AU2014201434A1 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PROVENTION BIO, INC.

Free format text: FORMER OWNER(S): MACROGENICS, INC.